The phase III FLAURA trial reported that osimertinib prolonged PFS and overall survival (OS) compared to first‐generation EGFR‐TKIs in the first‐line treatment of patients with EGFRm+ advanced NSCLC.8, 9. This evidence concerns the gene EGFR and non-small cell lung carcinoma.